Growth momentum masks margin compression; near-term freight headwinds vs multi-year EBITDA target

Revenue +24.9% YoY (₹433.4 Cr vs ₹346.9 Cr), PAT +23% YoY (₹39.6 Cr vs ₹32.2 Cr) — claims supported

EBITDA margin 15.1% vs 16.1% YoY (100 bps compression), PAT margin 9.1% vs 9.3% YoY (20 bps compression). One-off ₹8 Cr baryte charge and maintenance shutdown cited, but margins still below prior year

Strontium revenue ₹25 Cr achieved. Still in 'stabilization phase' at 50% capacity utilization; gross margins suboptimal, targeting 50%+ but not yet achieved. Yields improving

Barium standalone at 25% EBITDA (confirmed by management). One-off ₹8 Cr retrospective baryte charge in Q1 masked underlying margin, which management says 'will not recur'. Demand robust, sulphur byproduct values up 300–400%

Acquisition November 2025, refurbishment ongoing. Mgmt: 'expecting production anytime towards end of this month' (August 2026); volumes H2 FY27. Gross margin currently 44–45%, targeting 50%. Analyst Dhimant Shah challenged: 'no improvement visible'; mgmt deferred to 'end of year' for clarity

Q1 freight 9–10% of revenue; mgmt now guiding Q2 'could be upwards of 20%'. Only partial customer pass-through expected. This is a material near-term headwind not fully baked into guidance

Prior ~₹300 Cr FY27 → now ₹200–250 Cr. DMSO ₹205–240 Cr (₹68 Cr spent YTD), chromium ₹50 Cr, barium ₹40 Cr, South Africa ₹20–25 Cr. Reduction reflects scope or timing adjustment, not explicit in call.

Q1 guidance: 9–10% of revenue. Q2 revised to 'upwards of 20%'. Geopolitical Red Sea tensions cited. Material near-term margin headwind not flagged in prior call.

FY26 call: 'near-term volume increases from Strontium ramp in Q1 FY27.' Delivered: ₹25 Cr revenue but suboptimal margins. Management now: 'by end of year' expect 50% gross margins. Ramp slower than prior guidance.

Acquisition Nov 2025. Expecting 'anytime towards end of this month' (Aug 2026) production start, H2 volumes. Analyst Dhimant Shah flagged: no visible gross margin uplift yet. Mgmt defensive.

FY28 consolidated EBITDA margin target of 20% reaffirmed multiple times despite Q1 delivery at 15.1%. Not a raise; not a cut. Consistent with FY26 guidance.

10-year binding supply agreement for Chrome Oxide Green with European client (NDA-protected). Management: margin accretive, formula-driven pricing, high visibility. Expected signing imminently. New growth catalyst.

One-off ₹8 Cr retrospective baryte price charge (not recurring). Barium standalone targeting 25% EBITDA. Sulphur byproduct values up 300–400%. Demand robust. EU ADD on Chinese vendors adds 4–5% margin benefit (already captured). Freight headwind remains.

Chromium performed better this quarter due to product mix shift to value-added derivatives (50% vs 40% FY26). Shutdown did not materially impact revenues (inventory covered gap). Margin improvement from mix, not volume lost.

Stabilization phase; input/output ratios still suboptimal, will improve in quarters to come. Q1 revenue ₹24 Cr nearly full FY26 annual revenue (signal of scale). As chemistry improves and volumes ramp, margins will follow.

New line of activity; timelines as expected. Acquisition November 2025, 2-month transfer. Refurbishment ongoing. Production 'anytime towards end of this month', volumes H2 FY27. Relative advantage remains vs peers. By end of year, better clarity. Scalability in H2 will prove ROI.

Working on it; remains challenging and sensitive. Some peers (South Africa, Turkey) less impacted via Cape of Good Hope route. Partial pass-through on certain accounts. Strategy: shift to domestic sales for Q2 to mitigate; dynamic adjustments ongoing.

Combination: Strontium operational (new), barium capacity utilization and blended realization improved, chromium product mix shift to higher-value derivatives. Company does not quantify volume vs value split.

Total ₹200–250 Cr. DMSO ₹205–240 Cr (₹68 Cr spent YTD), Chromium ₹50 Cr, South Africa ₹20–25 Cr, Barium ₹40 Cr (backward integration). DMSO is majority, import replacement solvent for pharma/agro.

Very soon announcement (strategic in nature, linked to long-term supply/partnership). This will change product mix and business model. Long-term supply agreement for Chrome Oxide Green already being finalized with European client (NDA). Margin accretive, formula-driven, 10-year visibility.

Barium standalone at 25%. Strontium currently EBITDA positive but not at target margins; by end of year expect target levels with volume ramp. Combined barium + strontium (consolidated minus standalone chromium) should exceed 20%. Chromium improving on product mix.

Fixed volumes for next 10 years specifically for Chrome Oxide Green. Binding supply agreement, exchange plus logistics (not spot/quarterly). Take-or-pay structure; both parties obligated. Lot more strategic vs current spot sales. Margin accretive.

As of 31 Mar 2026 (FY26 close): ₹527 Cr total debt (long + short term), debt-to-equity 0.49. Quarterly balance sheet not shared; will update on Q2 results.

Management explicitly states 'we do not quantify quarterly or yearly guidance'; emphasis on year-on-year momentum instead of quarterly forecasting

FY27–FY28 capex ₹200–250 Cr targets new specialty chemicals and backward integration; commercialization timelines H2 FY27 → FY28. Organic growth from these drivers expected.

Long-term target reaffirmed multiple times (mentioned 8+ times in call). Driven by product mix upgrade, South Africa mining, DMSO, backward integration. No quarterly or FY27 margin target given. Mgmt acknowledged near-term headwinds (freight, macro) may delay path.

Confirmed by management. Demand robust, sulphur byproduct values elevated, export-driven. One-off ₹8 Cr baryte charge non-recurring.

Currently in stabilization phase; targeting end-of-year achievement at higher capacity utilization (65–75%). Yield improvements and chemistry optimization ongoing.

Shift to higher-value derivatives (50% of sales) contributing to margin improvement visible in Q1. Long-term supply agreement for Chrome Oxide Green (margin accretive) expected to provide sustained visibility. Commodity leather volume being phased down.

DMSO ₹205–240 Cr majority (₹68 Cr spent YTD); Chromium ₹50 Cr (value-added derivative expansion); Barium ₹40 Cr (backward integration); South Africa ₹20–25 Cr. Solar ₹5–6 Cr + SPV model.

Capex on track per plan; construction and equipment implementation progressing. First organic product for company; solvent for pharma/agro; import replacement.

FY27 spend ₹20–25 Cr for refurbishment/improvements. Acquisition cost sunk (Nov 2025). Production H2 FY27; margin impact dependent on volumes and ore quality alignment.

Q1 9–10% of revenue; Q2 guidance 'upwards of 20%' due to Red Sea geopolitical tensions. Partial customer pass-through. Could compress EBITDA margin by 300–500 bps sequentially if not managed. Management strategy: shift to domestic sales.

Acquisition Nov 2025; refurbishment still underway at call date (Aug 3, 2026). Volumes expected H2 FY27 but no fixed timeline. Gross margin currently 44–45%, target 50% by year-end 'ideally' (hard to quantify per mgmt). Analyst Dhimant Shah challenged: 'acquisition thesis is in jeopardy if no margin benefit visible.' Risk: ROI delayed to FY28 or beyond; capital allocation questioned.

Q1 revenue ₹25 Cr (achievement); at 50% capacity utilization; gross margins 'still suboptimal' per mgmt. Management: yields improving, chemistry optimizing, expect normalized margins by end FY27. Risk: margin uplift pushed beyond year-end; capex return on investment (capex for strontium plant) delayed. Full ramp-up to 65–75% utilization and 50%+ gross margin may slip.

Management promised 'very soon' announcement on chrome metal JV/partnership linked to long-term Chrome Oxide Green supply deal (10-year agreement). Details gated by NDA. Risk: delay in announcement or disappointing terms (lower margin accretion, smaller volumes, longer ramp). Also: technology transfer risk if JV partner is not vetted (mgmt: 'strategic partnership moving forward' but details withheld).

Leather industry demand remains 'challenging' per mgmt. Chrome ore a commodity linked to freight/logistics. Barium linked to infrastructure/real estate cycles in export markets (US, Latin America, Far East). Geopolitical tensions (West Asia) create volatility. Risk: demand softness in H2 FY27 if global growth stalls; pricing power limited on commodity products.